@ARTICLE{
author={Zamagni Elena,...,Bila Jelena S,...,(broj koautora 53)},
year={2024},
title={Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial},
journal={BLOOD},
volume={144},
number={},
pages={495-498},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Zamagni Elena,...,Bila Jelena S,...,(broj koautora 22)},
year={2022},
title={MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma},
journal={BLOOD},
volume={140},
number={},
pages={7289-7291},
document_type={Meeting Abstract},
}